Claudio Schuoler
Baar, ZG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: July 01, 2026
Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab.
Journal: Journal of asthma and allergy
Published: January 29, 2026
Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: March 28, 2025
Early and Sustained Response to Benralizumab in Severe, Eosinophilic Asthma: A Real-World Observational Study.
Journal: Journal of asthma and allergy
Published: October 18, 2024
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma
Journal: Praxis
Published: May 29, 2019
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma
Journal: Praxis
Published: May 29, 2019
Analysis of hypoxia-induced noncoding RNAs reveals metastasis-associated lung adenocarcinoma transcript 1 as an important regulator of vascular smooth muscle cell proliferation.
Journal: Experimental biology and medicine (Maywood, N.J.)
Published: January 07, 2017
Aquaporin 1 controls the functional phenotype of pulmonary smooth muscle cells in hypoxia-induced pulmonary hypertension.
Journal: Basic research in cardiology
Published: December 08, 2016
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: August 11, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026